# Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Article · Dhruv S. Kazi, Andrew Edward Moran, Pamela G. Coxson, Joanne M. Penko, Daniel A. Ollendorf, Steven D. Pearson, Jeffrey A. Tice, David Guzman, Kirsten B. Bibbins-Domingo

- Archive id: doi:10.1001/jama.2016.11004
- Published: 2016-08-16
- Venue: JAMA
- DOI: https://doi.org/10.1001/jama.2016.11004
- PMID: 27533159
- Citations: 382
- Source URL: https://doi.org/10.1001/jama.2016.11004
- PDF: https://jamanetwork.com/journals/jama/articlepdf/2544639/joi160091.pdf
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.